{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:48:28Z","timestamp":1782910108832,"version":"3.54.5"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study developed and validated a dynamic prediction model combining MRI features, clinical factors, and early treatment response to noninvasively predict long-term survival in unresectable hepatocellular carcinoma patients undergoing triple therapy (hepatic arterial infusion chemotherapy, targeted therapy, and immunotherapy).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study enrolled 223 patients from two centers, with 127 in the training set and 96 in the external set, evaluating imaging features and constructing a dynamic nomogram to predict 1-year and 2-year survival. Model performance was evaluated via bootstrap resampling and external validation. Decision curve analysis and SHapley Additive exPlanations (SHAP) analysis were employed to assess clinical utility and model interpretability. An R\/Shiny application was used for online deployment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>An imaging score was created based on five semantic features that suggest poor prognosis. The dynamic model, incorporating five semantic imaging features indicating poor prognosis, showed good discrimination, calibration, and clinical utility, especially when combining baseline and early treatment response. The predictive performance of the dynamic nomogram was numerically improved to that of BCLC staging and the traditional liver function grading system. SHAP analysis highlighted the imaging score as the most important predictor. The dynamic nomogram effectively stratified patients into low-, medium-, and high-risk groups, with significantly different survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A dynamic nomogram model that integrates baseline features and therapeutic response provides a noninvasive and effective tool for predicting prognosis and stratifying risk in uHCC patients receiving triple therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1848104","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:09:38Z","timestamp":1782907778000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dynamic nomogram integrating Gd-EOB-DTPA enhanced MRI semantic features, nutritional-inflammatory indices, and early treatment response to predict long-term survival in unresectable HCC treated with interventional, targeted, and immunotherapy: a multicenter retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"Rui-rui","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-yang","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-kang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-han","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Chongqing University Jiangjin Hospital, School of Medicine, Chongqing University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Chongqing University Jiangjin Hospital, School of Medicine, Chongqing University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-guo","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Chongqing Red Cross Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-ling","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuo-jin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]},{"name":"Chongqing Municipal Health Commission Key Laboratory of Precision Diagnosis and Treatment of Liver Cirrhosis and Complications","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","article-title":"Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review","volume":"10","author":"Cappuyns","year":"2024","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1430196","article-title":"Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111019","article-title":"Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: a retrospective study","volume":"125","author":"Zang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1615506","article-title":"Efficacy and safety of TACE-HAIC combined with tyrosine kinase inhibitors and immune checkpoint inhibitors for the patients with BCLC-defined stage B-C HCC","volume":"15","author":"Liu","year":"2025","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3892\/ol.2023.14121","article-title":"Efficacy and safety of hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"26","author":"Li","year":"2023","journal-title":"Oncol Lett"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1364345","article-title":"Efficacy and safety of PD-1 inhibitors plus anti-angiogenesis tyrosine kinase inhibitors with or without transarterial chemo(embolization) for unresectable hepatocellular carcinoma: a meta-analysis","volume":"14","author":"Chen","year":"2024","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1097\/meg.0000000000003012","article-title":"Efficacy and safety of hepatic artery infusion chemotherapy conjunction with tyrosine kinase inhibitors and programmed death-1 inhibitors for unresectable\/advanced hepatocellular carcinoma: a meta-analysis","volume":"37","author":"Xiao","year":"2025","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12916-025-04110-1","article-title":"Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib for advanced hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (Double-IA-001): a phase II trial","volume":"23","author":"Shen","year":"2025","journal-title":"BMC Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01663-6","article-title":"Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000000683","article-title":"Cost-effectiveness and prognostic model of hepatic arterial infusion chemotherapy for hepatocellular carcinoma with high tumor burden and\/or Vp4 tumor thrombus compared with sorafenib: a post-hoc analysis of the FOHAIC-1 trial","volume":"109","author":"Chen","year":"2023","journal-title":"Int J Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112551","article-title":"The ARH score, a practical guide to decision-making for retreatment with hepatic arterial infusion chemotherapy in hepatocellular carcinoma patients","volume":"138","author":"Mei","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40644-025-00885-x","article-title":"Histopathologic deep learning model for predicting tumor response to hepatic arterial infusion chemotherapy plus TKIs and ICIs in large hepatocellular carcinoma","volume":"25","author":"Lin","year":"2025","journal-title":"Cancer Imaging"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-025-01041-0","article-title":"Predicting the early therapeutic response to hepatic artery infusion chemotherapy in patients with unresectable HCC using a contrast-enhanced computed tomography-based habitat radiomics model: a multi-center retrospective study","volume":"48","author":"Wu","year":"2025","journal-title":"Cell Oncol (Dordrecht Netherlands)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-025-10877-5","article-title":"CT-based intratumoral and peritumoral radiomics to predict the treatment response to hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 in high-risk hepatocellular carcinoma cases: a multi-center study","volume":"19","author":"Liu","year":"2025","journal-title":"Hepatol Int"},{"key":"B17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41698-025-00979-6","article-title":"A multimodal fusion system predicting survival benefits of immune checkpoint inhibitors in unresectable hepatocellular carcinoma","volume":"9","author":"Xu","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1186\/s12885-025-13978-4","article-title":"Predicting treatment response and prognosis of immune checkpoint inhibitors-based combination therapy in advanced hepatocellular carcinoma using a longitudinal CT-based radiomics model: a multicenter study","volume":"25","author":"Xu","year":"2025","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mri.2022.01.006","article-title":"Quantitative evaluation of simultaneous spatial and temporal regularization in dynamic contrast-enhanced MRI of the liver using Gd-EOB-DTPA","volume":"88","author":"Murase","year":"2022","journal-title":"Magn Reson Imaging"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233229","article-title":"Gadoxetic acid-enhanced MRI scoring model to predict pathologic features of hepatocellular carcinoma","volume":"314","author":"Zhang","year":"2025","journal-title":"Radiology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ (Clinical Res Ed)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12072-023-10599-6","article-title":"Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations","volume":"18","author":"Zhao","year":"2024","journal-title":"Hepatol Int"},{"key":"B23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-025-01739-6","article-title":"Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy","volume":"18","author":"Dai","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J Hepatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.016","article-title":"Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma","volume":"57","author":"Personeni","year":"2012","journal-title":"J Hepatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.11613\/bm.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2018181494","article-title":"Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of hepatocellular carcinoma in at-risk patients","volume":"289","author":"Chernyak","year":"2018","journal-title":"Radiology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105948","article-title":"Evaluation and analysis of incidence and risk factors of lower extremity venous thrombosis after urologic surgeries: a prospective two-center cohort study using LASSO-logistic regression","volume":"89","author":"Tang","year":"2021","journal-title":"Int J Surg"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4097\/kja.19087","article-title":"Multicollinearity and misleading statistical results","volume":"72","author":"Kim","year":"2019","journal-title":"Korean J Anesthesiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.06.038","article-title":"Methodologic issues specific to prediction model development and evaluation","volume":"164","author":"Jin","year":"2023","journal-title":"Chest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01101","article-title":"Interpretation of compound activity predictions from complex machine learning models using local approximations and Shapley values","volume":"63","author":"Rodr\u00edguez-P\u00e9rez","year":"2020","journal-title":"J Med Chem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2022.09.049","article-title":"The advanced lung cancer inflammation index is the optimal inflammatory biomarker of overall survival in patients with lung cancer","volume":"13","author":"Song","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m441","article-title":"Calculating the sample size required for developing a clinical prediction model","volume":"368","author":"Riley","year":"2020","journal-title":"BMJ (Clinical Res Ed)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.s413283","article-title":"The predictive role of inflammatory biomarkers for treatment response and progression-free survival in patients with hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy with FOLFOX regimen: a preliminary study","volume":"10","author":"Zhao","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"B36","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1186\/s12885-024-12387-3","article-title":"Predictive nomograms based on gamma-glutamyl transpeptidase to prealbumin ratio for prognosis of hepatocellular carcinoma patients without microvascular invasion","volume":"24","author":"Ma","year":"2024","journal-title":"BMC Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"18147","DOI":"10.21203\/rs.3.rs-5624467\/v1","article-title":"Development and validation of a prealbumin-bilirubin model for prognostic prediction in intermediate hepatocellular carcinoma undergoing transarterial chemoembolization","volume":"15","author":"Jiang","year":"2025","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cytogfr.2024.08.006","article-title":"Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis","volume":"79","author":"Yu","year":"2024","journal-title":"Cytokine Growth Factor Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1848104\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:09:40Z","timestamp":1782907780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1848104\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2026.1848104"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1848104","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1848104"}}